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Recombinant human granulocyte colony-
stimulating factor enhanced the resolution of
venous thrombi
Yi-kuan Chen, MD,a Xue-mei Jiang, MSc,b and Jian-ping Gong, MD,a Chongqing, Peoples Republic of China
Background: Bone marrow–derived cells are recruited into the thrombus during resolution. This study explored whether
mobilization of bone marrow cells with recombinant human granulocyte colony-stimulating factor (rhG-CSF) could
enhance the resolution of venous thrombi and the accumulation of macrophages in thrombi and explored the effect of
rhG-CSF on cysteine-cysteine chemokine receptor 2 (CCR2) expression.
Methods:The Sprague-Dawley adult rats were randomly divided into four groups: control, sham-operated, thrombus, and
treatment groups. Thrombi were induced in the thrombus and treatment group, which received a subcutaneous injection
of rhG-CSF once daily for 6 days postoperatively. The thrombus, sham-operated, and control groups received equal
volumes of 0.9% saline. The mononuclear cells in peripheral blood were analyzed by an automated hematology analyzer
and counted under microscope. The cell marker CD68 was used to determine the number of macrophages in thrombi
tissue sections. Levels of monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1
(MIP1) in the peripheral blood were detected by enzyme-linked immunosorbent assay. Real-time reverse transcriptase–
polymerase chain reaction and Western blot were used to analyze, respectively, the expression of CCR2 messenger RNA
in the peripheral blood and CCR2 protein of THP-1 monocyte.
Results: At postoperative days 3 (P < .05) and 7 (P < .01), mononuclear cells significantly increased in treatment group
(2.1  0.3, 4.4  0.3  106/L) vs the thrombus group (1.7  0.2, 1.3  0.4  106/L). The organization and
recanalization of thrombi in treatment group progressed more quickly compared with the thrombus group (P< .01). The
macrophage number of the thrombus in the treatment group (338  26 cells/15 high-power fields) increased
significantly vs the thrombus group (125 11 cells/15 high-power fields, P< .01). No statistical difference was observed
between the thrombus and treatment group in the MCP-1 and MIP-1 level in peripheral blood. Expressions of the
CCR2 gene in the peripheral blood of the treatment group significantly increased compared with the thrombus group
(P < .05). Recombinant human G-CSF induced higher expression of CCR2 protein of human monocytic cell line THP-1.
Conclusions: Bone marrow mobilization enhanced the resolution and recanalization of venous thrombi. This process was
associated with increased macrophage accumulation in thrombi, which might be the result of higher CCR2 expression of
monocytes. ( J Vasc Surg 2008;47:1058-65.)
Clinical Relevance. The classic treatment of venous thrombi is anticoagulation. Anticoagulant therapy and thrombolysis
both have limited effects on existing thrombi and have a small but significant risk of severe hemorrhage. In clinical
practice, we lack specific treatment for patients with venous thrombosis combined with brain hemorrhage or a
gastrointestinal activated ulcer, which are contraindicated for anticoagulation and thrombolytic therapy. Enhancing the
resolution of venous thrombi would contribute to its therapy. Bone marrow–derived cells are recruited into the thrombus
during resolution. Many of these cells express a macrophage phenotype and may represent a population of plastic stem
cells that orchestrate thrombus recanalization. Recombinant human granulocyte colony stimulating factor (rhG-CSF)
can mobilize monocytic lineage cells into peripheral blood and may contribute to this cell in the thrombi. If rhG-CSF
enhances the resolution of venous thrombi and recanalization, it might be used to treat patients with venous thrombi,
especially those who have contraindication for anticoagulation and thrombolytic therapy.The annual incidence of venous thrombosis is between
100 and200per 100,000of the general population according
to recent estimates made in Europe and North America.1
Anticoagulant therapy and thrombolysis both have limited
effects on the existing thrombi and have a small but significant
From the Departments of General Surgery,a and Haematology,b Second
Affiliated Hospital, Chongqing University of Medical Science.
This research was supported in part by PhD Programs Foundation of
Ministry of Education of China (20050631001).
Competition of interest: none.
Reprint requests: Dr Jian-ping Gong, Department of General Surgery,
Second Affiliated Hospital, Chongqing University of Medical Sciences,
Chongqing 400010, PR China (e-mail: cyikuan6688@yahoo.com.cn).
0741-5214/$34.00
Copyright © 2008 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2007.12.042
1058risk of severe hemorrhage. In clinical practice, we lack specific
treatment for patientswith venous thrombosis combinedwith
brain hemorrhage or gastrointestinal activated ulcer in whom
anticoagulation and thrombolytic therapy is contraindicated.
Venous thrombi resolve naturally by a slow process of
organization and recanalization.2 As thrombus organize,
neutrophils, monocytes, and endothelial cells enter into
the thrombus, and new vessels appear within the body of
the thrombus. These coalesce and enlarge, and blood
flow is eventually established through the thrombus.
Bonemarrow–derived cells are recruited into the thrombus
during resolution. Many of these cells express a macro-
phage phenotype and may represent a population of plastic
stem cells that orchestrate thrombus recanalization.3 En-
hancing organization and recanalization of thrombus may
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lar damage and residual obstruction and also be valuable
when anticoagulation and thrombolysis are contraindicated
for the therapy of venous thrombosis.
Monocyte chemoattractant protein-1 (MCP-1) and
macrophage inflammatory protein-1 (MIP-1) are the
main chemokines of monocytes/macrophages. In periph-
eral blood, cysteine-cysteine chemokine receptor 2 (CCR2)
expression is largely limited to monocytes. CCR2 is critical
in monocyte recruitment, and enhancing the expression of
CCR2may contribute to macrophages accumulation in the
thrombi.
Recombinant human granulocyte colony-stimulating
factor (rhG-CSF) has frequently been used formobilization
of bonemarrow stem cells in human and animal research.4,5
The purpose of this study was to explore whether mobi-
lization of bone marrow cells with rhG-CSF could en-
hance the resolution of venous thrombi and macrophage
accumulation in thrombi as well as investigate the effect
of rhG-CSF on CCR2 expression.
METHODS
Rat model of venous thrombosis. Thrombus was
produced in the left infrarenal vena cava of animals as
Modarai described 3 and modified. A midline laparotomy
was performed to expose the infrarenal portion of the vena
cava. The segment of the vena cava from just below the left
renal vein to the confluence of the common iliac veins was
dissected and the tributaries were ligated. A neurosurgical
vascular clip (B. Braun Medical, Bethlehem, Pa) was ap-
plied to this portion of the vein for 60 seconds on 2
occasions, 30 seconds apart, to induce endothelial damage.
A length of 5-0 polypropylene suture was then placed
alongside the vena cava. A stenosis was produced in the vein
by tying a 4-0 silk suture around the vena cava to include
the polypropylene suture. The polypropylene suture was
then pulled out to allow some flow within it and induce
blood stasis. Endothelial damage and blood stasis promote
thrombus formation rather than a blood clot. The intes-
tines were replaced, and the abdominal wall was sutured.
The animals were then allowed to recover from the anes-
thesia and given access to water and rat chow.
Groups of animals. Adult male Sprague-Dawley rats
(weight, 190  10 g; age, 8-9 weeks) were used. The
animals were allowed free access to water and standard
laboratory rat chow. The study design was approved by the
Ethics in Research Committee of Chongqing University of
Medical Science.
The animals were assigned to four groups of 10 rats each.
The treatment groupunderwent induced venous thrombi and
bone marrow cell mobilization with a once-daily 25-g/kg
subcutaneous injection of rhG-CSF (Shenzhen Xinpeng Bio-
technology Co, Shenzhen, China) for 6 days postopera-
tively.4,5 The thrombus groupunderwent the venous thrombi
induction procedure. The sham-operated group underwent
the same procedure, except a silk ligature was passed around
the left infrarenal vena cava but left untied. The rats in the
control group did not undergo any procedures. The throm-bus, sham-operated, and control groups received equal vol-
umes of 0.9% salinewith subcutaneous injection once daily for
6 days postoperatively. The rats in each cohort were humanly
killed days 10 after operation. Samples of whole blood were
collected from each animal by tail cut.
Tissue harvesting. At postoperative day 10, rats were
reanesthetized and a laparotomy was performed to excise
the infrarenal vena cava, which was prepared for histology
and image analysis, from just above the ligature to the
confluence of the common iliac veins.
Histology. The infrarenal vena cava that contained
the thrombus was fixed in 4% paraformaldehyde overnight
and embedded in paraffin wax. Transverse sections (5-m
thick) were cut at 150-m intervals below the ligature
throughout the length of the sample and stained with
hematoxylin and eosin. This produced between 10 and 15
sections of each thrombus for analysis. Sections of tissues
were viewed at 40 magnification. High-magnification
(400) images were obtained for the whole section area
and tiled to make a single composite with image analysis
software (Image Pro Plus 5.0, Media Cybernetics, Inc.
Bethesda, Md). Sections were digitized using a microscope-
mounted camera (Coolpix 3700, Nikon, Tokyo, Japan).
The area of thrombus and the thrombus organization area
in each section were measured with the same software. The
organization rate of each section was expressed as a per-
centage of organization area at thrombus. All sections of
each animal were analyzed, and an average value was calcu-
lated as the organization rate of that animal. All the images
were analyzed blindly.
Macrophage number. Paraffin sections of the throm-
bus were taken at postoperative day 10 from the treatment
and thrombus groups (n 10 per group). The sections were
processed for immunohistochemistry to localizemacrophages
using the monoclonal antibody (Lab Vision, Fremont, Calif)
raised against theCD68 antigen. The antigenwas retrieved by
microwaving at 650 W for 10 minutes in citrate buffer (pH,
6.0). Primary antibody binding was located using a biotinyl-
ated second antibody, followed by a streptavidin-peroxidase
complex. The macrophages (CD68-positive stained cells) in
the thrombus were counted and totaled in five high-power
fields (1000magnification) radially in each of three sections
taken from the 150-m intervals below the ligature of the
vena cava.
Detection of peripheral blood mononuclear cells.
Peripheral blood was collected preoperatively and at days 3
and 7 postoperatively. An automated hematology analyzer
(Sysmex XT-2000i, Roche Diagnostics, Indianapolis, Ind)
was used to detect the white blood cells, and a microscope
was used to count the percentage of mononuclear cells in
the white blood cells.
Cell culture. The human monocytic cell line THP-1
was purchased from the Center for Lipid Research (Chong-
qing University of Medical Science). The THP-1 cells were
grown in Roswell Memorial Institute Medium (RPMI)-
1640 supplemented with 100 U/mL penicillin, 100
g/mL streptomycin, and 10% fetal bovine serum (Sigma,
St Louis, Mo) in 5% carbon dioxide in air at 37°C. Cells
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100-mL culture flask. The THP-1 cells were cultured for
48 hours in culture medium contained rhG-CSF with
concentrations of 0, 20, 40, 80, 160, and 320 ng/mL as
well as for 36, 48, and 60 hours in 80 ng/mL concentration
to determine the rhG-CSF effect on CCR2 protein expres-
sion of TPH-1 cells.
Enzyme-linked immunosorbent assay. The levels of
MCP-1 and MIP-1 in peripheral blood were analyzed by
using sandwich enzyme-linked immunosorbent assays
(ELISA). Assays were conducted using rat MCP-1 and
MIP-1ELISAkits (AntigenixAmerica,Huntington Station,
NY) in accordance with the manufacturer’s instructions.
Real-time reverse transcriptase–polymerase chain
reaction. The total RNA was prepared from each sample
using a blood RNA mini-kit (Catrimox-14TM RNA Isola-
tion Kit 2.11, Takara Biotechnology Company, Dalian,
China) according to the protocol recommended by the
manufacturer and stored at80°C until use. A quantitative
real-time reverse transcriptase–polymerase chain reaction
(RT-PCR) assay was performed to measure the rat CCR2
messenger RNA (mRNA) in peripheral blood with the ABI
Prism 7000 sequence detection system using TaqManUni-
versal PCR Master Mix (both Applied Biosystems Inc,
Foster City, Calif) according to the manufacturer’s specifi-
cations.
Polymerase chain reaction primers for rat CCR2 and
-actin were designed by Takara Biotechnology Company,
Dalian, China. The forward and reverse primers used for
CCR2 region were 5=-TGTTCTCTTCCTGACCACC-
TTC-3= and 5=-GACTTCTTGCTCCCCAGTAGA-3=.
The internal CCR2 TaqMan probe was 5=-CTGAC-
CACCTTCCAGGAATTCTT-3=, which carried a 5= re-
porter dye FAM (6-carboxy fluorescein) and a 3= quencher
dye TAMRA (6-carboxy tetramethyl rhodamine).
To quantify the rat -actin gene, the forward and reverse
primers were 5=-GACCCAGATCATGTTTGAGACC-3=
and 5=-GCAGTAATCTCCTTCTGCATCC-3=, and the in-
ternal -actin TaqMan probe was 5=-CCATCCAGGCTGT-
GTTGTCCC-3=.
The PCR amplification conditions were one cycle at
42°C for 30minutes and at 95°C for 5minutes, 40 cycles of
denaturation at 95°C for 15 seconds, and annealing/exten-
sion at 60°C for 45 seconds. PCR was done in triplicate for
each sample. Data were presented as relative induction of
CCR2 normalized to -actin.
Western blot. Protein fromTPH-1 cells was extracted
according to the manufacture’s instructions with a Cell &
Tissue Protein Extraction Reagent (KangChen Bio-tech,
Shanghai, China). To prevent phosphatase activity, all pro-
cedures were performed on ice and phosphatase inhibitors
were added. Protein content was quantified with a BCA
Protein Quantity Kit with bovine serum albumin standard
(KangChen Bio-tech). Lysates (50 g) underwent immuno-
blot analysis in 12% sodium dodecyl sulfate-polyacrylamide
gels under 60 mA, followed by electrotransfer to polyvinyli-
dene difluoride (PVDF) blotmembranes. Themembranewas
blocked for 1 hour in Tris-buffered saline-Tween supple-mented with 5% bovine serum albumin. The membrane was
incubated with goat antihuman CCR2 antibody (final
dilution, 1:1,000; Abcam Inc, Cambridge, Mass), fol-
lowed by washes and incubation with horseradish
peroxidase–conjugated rabbit antigoat immunoglobulin
(Ig) G antibody (final dilution, 1:5,000; Jackson Immu-
noResearch Laboratories Inc, West Grove, Pa).
A rabbit antihuman glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) antibody was used to assess the
levels of protein loaded per lane. The GAPDH antibody
(final dilution, 1:1,000; Abcam) was then incubated with
the membrane, followed by washes and incubation with
horseradish peroxidase– conjugated goat antirabbit IgG
antibody (final dilution, 1:5,000, Jackson). The proteins
were detected with a 3,3=-Diaminobenzidine (DAB) kit
(Sigma). The immunoblots were semi-quantified by den-
sitometric scanning with computer image software (Im-
age Pro Plus5.0).
Statistical analysis. Data were presented as mean 
standard error of the mean. One-way analysis of variance,
followed by Bonferroni (Dunn) t tests, was used to assess
differences between groups. Statistical significance was as-
sumed for P  .05. Data were analyzed with SAS 9.1
software (SAS Inc, Cary, NC).
RESULTS
Mononuclear cells in peripheral blood. Because
rhG-CSF could mobilize bone marrow stem cells into
peripheral blood, we used an automated hematology ana-
lyzer to quantify mononuclear cells in the peripheral blood.
Mononuclear cells significantly increased in the rhG-CSF
treatment group on postoperative days 3 and 7 compared
with the thrombus and control groups (Table).
Histologic findings. No thrombus formed in the rats
in the sham-operated group. Thrombus was induced in all
rats of the treatment and thrombus groups and consisted of
a laminated structure composed of layers of fibrin inter-
spersed with platelets and red blood cells. Compared with
the thrombus group (30.6% 3.5%), the organization rate
of the treatment group (80.2%  10.8%) at days 10 was
significantly different (P  .01). High-power microscopic
Table. Detection of mononuclear cells of peripheral
blood in groups (n  10)




Pre-op 1.3  0.3 1.4  0.2 1.2  0.3 1.4  0.4
Post-op, day 3 1.3  0.2 1.5  0.3 1.7  0.2 2.1  0.3a
Post-op, day 7 1.3  0.2 1.3  0.3 1.3  0.4 4.4  0.3b
aP  .05; bP  .01. Mononuclear cells significantly increased in treatment
group at postoperative days 3 and 7 compared with thrombus group (P 
.05, P  .01) and control (P  .05, P  .01). There were no significant
difference between sham group and thrombus group (P 	 .05) at postop-
erative days 3 and 7.examination showed many neovessels at the organization
mbu
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the thrombus group at postoperative day 10 (Fig 1).
Numbers of macrophages in the thrombus.
Fig 1. Organization of thrombi in thrombus group (ThG)
The red arrows indicate the organization area of thromb
monocytes, and endothelial cells entered into the thromb
organization rate was significantly different in the treatment
group (30.6%  3.5%). A, Organization of thrombi in th
thrombi.B, Organization of thrombi in the treatment grou
[HE], originalmagnification40).C,Fewneovessels appe
D, Many neovessels formed at the organization area of thro
enlarged (HE original magnification100).Compared with the thrombus group (125 11 cells/15high-power fields) at postoperative day 10, the treatment
group had a significantly increased number of macro-
phages, shown by CD68 staining, in the thrombus (338
reatment group (TrG) at postoperative day 10 (%, n10).
organization of venous thrombi occurred, neutrophils,
eovessels appeared, and thrombus collagen formed. The
p (80.2% 10.8%; P .01) compared with the thrombus
mbus group was mainly located at the peripheral area of
lved almost all areas of the thrombi (hematoxylin and eosin
t the organization area of thrombus in the thrombus group.






ared a 26 cells/15 high-power fields, P .01). Many neoves-
11 cells/15 high-power fields; P  .01).
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(Fig 2).
Levels of monocyte chemoattractant protein-1 and
macrophage inflammatory protein-1. Compared with
the control group, the level of MCP-1 and MIP-1 in the
three operation groups significantly increased at postoper-
ative day 3 (P  .01) and had no statistical difference at
postoperative day 7. The level of MCP-1 and MIP-1 had
no statistical difference at postoperative days 3 and 7 be-
tween the thrombus group and treatment group.
Expression of cysteine-cysteine chemokine receptor
2 messenger RNA. Fig 3 summarizes the real-time
RT-PCR results of the peripheral blood obtained from
rats in the control, sham-operated, thrombus, and rhG-
CSF treatment groups preoperatively and on postopera-
tive days 3 and 7. The transcripts of the CCR2 gene were
significantly increased after operation in the sham-
operated, thrombus, and treatment group (P  .05).
The transcripts of the CCR2 gene did not significantly
change between the sham-operated and thrombus group
but were significantly increased in the rhG-CSF treat-
ment group compared the thrombus group at postoper-
ative days 3 and 7 (P  .05).
Expression of cysteine-cysteine chemokine receptor
2 protein. Expression of CCR2 protein by TPH-1 cells
was analyzed by Western blot. After 48 hours, it peaked at
80-ng/mL rhG-CSF stimulation and then declined (Fig
4). Expression of CCR2 protein significantly increased
from 36 hours of 80-ng/mL rhG-CSF stimulation, and a
considerably high level of expression started from 48 hours
Fig 3. Expression of the cysteine-cysteine chemokine receptor 2
(CCR2) gene in the peripheral blood of the four experimental
groups. Real-time reverse transcriptase–polymerase chain reaction
of each transcript was performed. Results are presented as relative
units of each CCR2 transcript compared with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). NG, Normal (control)
group; SG, sham operation group; ThG, thrombus group; TrG,
treatment group. P .05 compared with thrombus group. Error
bars show the standard error of the mean.Fig 2. Immunohistochemical CD68 stain of thrombi in throm-
bus group (ThG) and treatment group (TrG) at postoperative
day 10 (Streptavidin-biotin-peroxidase complex, original mag-
nification400). Macrophages stained brown and are indicated
by the red arrows. A, A few macrophages at vein wall (W) and
thrombus (T) in the thrombus group. Error bars show the
standard error of the mean. B, Many macrophages and neoves-
sels are seen at the thrombus in the treatment group. The
neovessels mostly appeared at areas where macrophages accu-
mulated. The macrophage number in the thrombus was signif-
icantly increased in the treatment group (338  26 cells/15
high-power fields) compared with the thrombus group (125(Fig 5).
error
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Different methods are used to induce venous thrombi
in animals, including venous ligation, stenosis,6 vein stasis
and injection of thromboplastin,7 and ferric chloride injury
of the vein wall, 8 among others. This study used mechan-
ical injury of the vein wall combined with venous stenosis to
induce formation of venous thrombi as Modarai et al3
described and modified. The thrombi were successfully
induced in all animals of the thrombus and treatment
groups in this study, which showed that this procedure was
stable to induce venous thrombi. Venous stenoses slows the
blood flow, and the injury of the vein wall promotes coag-
ulation. These thrombi were similar to the venous thrombi
that occur in humans and were adapted to study recanali-
zation and organization of thrombi.
In this study, after subcutaneous daily injections of
rhG-CSF for 6 days, the number of white blood cells and
mononuclear cells in the peripheral blood significantly in-
Fig 4. Left, Cysteine-cysteine chemokine receptor 2 (C
concentration of recombinant human granulocyte colon
blot analysis for 48 hours. Right, Graph shows combine
7 were the markers and 0, 20, 40, 80, 160 and 320 ng/
Glyceraldehyde-3-phosphate dehydrogenase. *P  .05
standard error of the mean.
Fig 5. Left, Expression of cysteine-cysteine chemokine
granulocyte colony-stimulating factor treated TPH-1 ce
hours. GAPDH, Glyceraldehyde-3-phosphate dehydrog
culturing flasks. Compared with 36 hours of culture, th
from 48 hours. P  .01. Error bars show the standardcreased at days 3 and 7 in treatment group, but no signifi-cant change occurred in the nontreatment groups. This
showed that it was the rhG-CSF, not the thrombi or
surgical trauma, that effectivelymobilized the bonemarrow
stem cells of the rats. Previous study showed rhG-CSF was
frequently used in mobilization of bone marrow stem cells
in humans and rats.4,5
Recombinant human G-CSF mobilizes a variety of
bone marrow stem cells entering into peripheral blood,
including hematopoietic stem cells, endothelial progenitor
cells, and putative smooth muscle progenitor cells9 and
monocytes.10 These cells were among the mononuclear
cells that weremobilized into the peripheral blood. Recom-
binant human G-CSF also promotes mobilized cells to
differentiate and proliferate. These effects of rhG-CSF may
contribute to mobilized monocytes entering into thrombi
and promote resolution and recanalization of thrombi.
In this study, the accumulation of macrophages in
thrombi increased after mobilization of bone marrow stem
protein expression of TPH-1 cells treated with different
ulating factor (rhG-CSF) was determined by Western
lts from three culturing flasks. Lanes 1, 2, 3, 4, 5, 6 and
as the respective concentration of rhG-CSF. GAPDH,
 .01 compared with 0 ng/mL. Error bars show the
tor 2 (CCR2) protein in 80 ng/mL recombinant human
determined by Western blot analysis for 36, 48 and 60
. Right, Graph shows the combined results from three








ere wcells by rhG-CSF and the organization and recanalization
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transplanting wild-type bone marrow restored thrombus
resolution in gene-knockout animals, suggesting bone
marrow–derived cells are important in this process.11 Bone
marrow–derived cells, however, did not line the new re-
canalizing channels that formed between the thrombus and
the venous wall or within the thrombus itself.3 Direct
administration of peritoneal macrophages decreased
thrombus size by more than fivefold and increased recana-
lization by more than fourfold compared with controls,12
so increasing the macrophage number in thrombi might
contribute to its resolution. The mechanism of rhG-CSF–
inducedmacrophage accumulation in thrombi was unclear.
Increasing the numbers of monocyte induced by rhG-CSF
in the peripheral blood might not naturally increase its
accumulation in thrombi.
The main chemoattractants of the monocytes/macro-
phages were MCP-1 and MIP-1. Cysteine-cysteine che-
mokine receptor 2 was largely limited to monocytes in the
peripheral blood. This study showed that rhG-CSF had no
effect onMCP-1 andMIP-1 levels in the peripheral blood
of rats, CCR2 mRNA expression significantly increased in
the peripheral blood of the group treated with the rhG-CSF
injection compared with nontreatment groups, and rhG-
CSF increased CCR2 protein expression of THP-1 mono-
cytes according to the Western blot analysis.
A previous study showed that when immortalized bone
marrow progenitors were induced by G-CSF to differenti-
ate into mature neutrophils, the CCR2 gene was strongly
activated.13 Deletion of CCR2 or blockade of all CC che-
mokines inhibited both monocyte recruitment and throm-
bus resolution.12 Genetic deletion of CCR2 was associated
with larger thrombi, increased thrombus collagen, fewer
thrombus monocytes, reduced matrix metalloproteinase-2
and 9 activity, and significantly impaired neovasculariza-
tion.14 Cysteine-cysteine chemokine receptor 2 and MCP-
3/MCP-1 were critical for monocyte mobilization from
bone marrow and recruitment into inflammatory sites,
whereas MCP-2 and MCP-5 have no effect on monocytes
mobilization and recruitment.15 These results showed that
the increase of macrophage accumulation in thrombi after
rhG-CSF treatment might result from increasing monocyte
CCR2 expression in the peripheral blood and bone marrow
cell mobilization induced by rhG-CSF.
Macrophage accumulation in the thrombi induced by
rhG-CSF might not have a relationship with MCP-1 and
MIP-1 expression in the peripheral blood. The increase of
bone marrow–derived monocyte CCR2 expression in pe-
ripheral blood might therefore increase the chemotaxis of
monocytes to recruit into thrombus. Expression of che-
moattractants MCP-1 and MCP-3 in thrombus may be
involved in regulating the recruitment of bone marrow–
derived monocytes into thrombus.
How the macrophages contribute to recanalization of
thrombus was unclear. As previous study shown, mono-
cytes can express a variety of proteases, including metallo-
proteases, which can degrade extracellular matrix to
facilitate migration.16 Monocytes can also remove fi-brin through receptor-mediated lysosomal degradation.17
Monocytes/macrophages have been implicated in angio-
genesis through their capacity to produce many potent
angiogenic factors, such as tumor necrosis factor-, basic
fibroblast growth factor, and vascular endothelial growth
factor (VEGF).18,19 The accumulation of macrophages in
thrombus might lead to an increase of these angiogenic
factors in local expression. Macrophages derived from bone
marrow, which mostly express the VEGF cell marker, were
present mainly at the periphery of the thrombus at days 7
and throughout the thrombus at days 14.3 Recanalization
of thrombus mostly emerged at areas with macrophage
accumulation, as previously observed.20 VEGF gene ther-
apy for venous thrombus resulted in smaller thrombi with
greater recanalization.21 There were two populations of
macrophages M1 and M2. Bone marrow–derived mono-
cytes showed M1 or M2 phenotype according to different
tumor stage.22 The M1 macrophages act as potent proin-
flammatory cells that destroy microorganisms and tumor
cells, whereasM2macrophages express scavenger receptors
A and B, CD163, mannose receptor, CD14, CD23, inter-
leukin (IL)-10, IL-1r, and polyamines, temper the Th2
inflammatory response, and promote angiogenesis and tis-
sue remodeling. So we extrapolate that it may be mainly
M2 macrophages that are mobilized into the thrombus.
In conclusion, to our knowledge, this is the first study
that directly shows the role of bone marrowmobilization in
thrombus resolution.
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